Europe’s biggest cancer congress ESMO wraps up today, having delivering its fair share of major studies and talking points in cancer treatment over five days.
New phase 3 data presented at ESMO earlier today suggests Tagrisso could be a major step forward in treating patients with EGFR positive non-small cell lung cancer.
While cancer continues to be one of the leading causes of death and illness, new technology and increasing use of real-world data have the potential to revolutionise care.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.